1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------
FORM 10-Q/A-1
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For Quarter Ended: November 25, 1995
-----------------
Commission File No: 0-10824
-------
GENOME THERAPEUTICS CORP.
-------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
MASSACHUSETTS 04-2297484
------------- ----------
(STATE OR OTHER JURISDICTION (I.R.S. EMPLOYER
IDENTIFICATION OF INCORPORATION OR ORGANIZATION) NO.)
100 BEAVER STREET; WALTHAM, MASSACHUSETTS 02154
------------------------------------------ -----
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT'S TELEPHONE NUMBER: (617) 893-5007
--------------
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
--- ---
Indicate the number of shares outstanding of each of the issuer's classes
of Common Stock, as of the latest practicable date.
COMMON STOCK 13,751,011
------------ ---------------------------
$.10 PAR VALUE Outstanding January 3, 1996
SERIES B RESTRICTED STOCK 57,512
------------------------- ---------------------------
$.10 PAR VALUE Outstanding January 3, 1996
2
Part II
-------
Item 6. Exhibits and Reports on Form 8-K
--------------------------------
a) Exhibits:
---------
10.29 Collaboration and License Agreement between the Company,
Schering Corporation and Schering-Plough Ltd. dated as of
December 6, 1995.
b) Reports on Form 8-K
-------------------
None.
12
3
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has caused this amended report to be signed on its behalf by the
undersigned thereunto duly authorized who also serves in the capacity of
principal financial officer.
Genome Therapeutics Corp.
/s/ Fenel M. Eloi
-----------------------------
Fenel M. Eloi
(Principal Financial Officer)
Date: February 13, 1996
13